Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Pharma
Delayed FDA nod moves Lilly into crowded ulcerative colitis field
With a new FDA approval, Lilly’s mirikizumab has become the first IL-23 inhibitor to enter the crowded ulcerative colitis field.
Angus Liu
Oct 27, 2023 11:10am
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara
Oct 16, 2023 10:07am
AbbVie's Skyrizi deals blow to J&J's Stelara in IBD trial
Sep 12, 2023 11:26am
AbbVie's Skyrizi delivers ulcerative colitis maintenance win
Jun 15, 2023 11:48am
AbbVie enlists ex-baseball star to destimagtize bowel disease
Jun 15, 2023 10:00am
FDA rejects Lilly's IBD drug thanks to manufacturing shortfall
Apr 14, 2023 10:51am